Chlorpromazine (CPZ), the first widely used phenothiazine tranquilizer, is shown to inhibit the action of intracellular calmodulin (CaM) and bone resorption in vivo and in vitro. In this study, CPZ (0.63 -10 μM) dose-dependently inhibited the formation of tartrate-resistant acid phosphatase (TRAP) staining-positive osteoclast-like cells in mouse bone marrow cells (BMCs) treated with 1α,25(OH) 2 D 3 (10 nM) or soluble receptor activator of nuclear factor-κB ligand (s-RANKL) (20 ng/ml). Expressions of mRNA for the nuclear factor of activated T-cells c1 (NFATc1), a key regulator of osteoclast differentiation; dendritic cell-specific transmembrane protein (DC-STAMP), an essential protein for cell-cell fusion; and characteristic markers of osteoclasts such as TRAP, cathepsin K, carbonic anhydrase II, and calcitonin receptor in BMCs were up-regulated by s-RANKL and decreased by the addition of CPZ (5 μM) or the selective CaM antagonist W7, but not the inactive analog W5. The general CaM kinase (CaMK) inhibitor KN-93 and CaM-dependent phosphatase calcineurin inhibitor FK-506 also inhibited s-RANKL-induced osteoclastogenesis. Phenothiazines such as CPZ, trifluoperazine (TFPZ), and promethazine (PMZ) inhibited s-RANKL-induced osteoclast-like cell formation in mouse BMCs. Osteoclastogenesis inhibitory effects decreased in the order of TFPZ, CPZ, PMZ, depending on their anti-CaM potency. These findings suggest that CPZ inhibits RANKL-induced osteoclastogenesis by its anti-CaM action.
Introduction
Chlorpromazine (CPZ), the first widely used phenothiazine tranquilizer, possesses potent tranquilizing and antiemetic properties, which have led to its widespread use in various fields of medicine. Phenothiazine antipsychotics are known to inhibit calmodulin (CaM), a ubiquitously distributed intracellular calcium-receptive protein, the most important transducer of Ca 2+ signaling in various physiological processes (1, 2) . Apart from antipsychotic actions, effects on bone metabolism have been shown by phenothiazine derivatives such as CPZ, promethazine (PMZ), and trifluoperazine (TFPZ). CPZ decreased alkaline phosphatase activity in mouse osteoblastic cells, suggesting the inhibition of osteoblastic function (3, 4) . On the other hand, CPZ and PMZ inhib-ited bone resorption by isolated osteoclasts in the bone slice assay (5, 6) and parathyroid extract-induced bone resorption in mouse calvaria (7) . TFPZ inhibited osteoclast formation in mouse bone marrow macrophages (8) . CPZ reduced alveolar bone loss in experimental periodontal disease in rats (9) . These evidences suggest that phenothiazine derivatives inhibit not only osteoblastic function but also osteoclastic bone resorption.
Osteoclasts are bone-resorbing multinucleate large cells derived from the hematopoietic monocyte-macrophage lineage, expressing characteristic markers such as tartrate-resistant acid phosphatase (TRAP), calcitonin receptor (CTR), carbonic anhydrase II (CAII), and cathepsin K (10 -12) . In addition, dendritic cell-specific transmembrane protein (DC-STAMP), an essential molecule for cell-cell fusion, was recently identified (10 -15) . It is well known that bone-resorbing agents such as 1α,25(OH) 2 D 3 , parathyroid hormone, and prostaglandin E 2 (PGE 2 ) increase the receptor activator of nuclear factor-κB (RANK) ligand (RANKL) production in osteoblasts/stromal cells to induce the formation of osteoclast-like cells from precursors (10, 16, 17) . The precise molecular mechanisms underlying osteoclast differentiation have been clarified in recent studies by Takayanagi's group (18 -23) . They showed that the binding of RANKL to RANK in osteoclast precursor cells specifically induced the expression of the nuclear factor of activated T-cells c1 (NFATc1), a key regulator of osteoclast differentiation. They also showed that RANKL evoked Ca 2+ oscillations in osteoclast precursor cells leading to Ca 2+ -CaM-calcineurin-mediated activation of NFATc1. Furthermore, Sato et al. (23) clarified that the Ca 2+ -CaM-dependent kinase (CaMK) -cAMP response element-binding protein (CREB) pathway is crucial for osteoclast differentiation and function; namely, they demonstrated that pharmacological inhibition of CaMKs as well as the genetic ablation of CamK4 reduced CREB phosphorylation and downregulated the expression of c-FOS, which is required for the induction of NFATc1. Consistent with these studies, Seales et al. (24) demonstrated that CaM is a critical regulator of osteoclastic differentiation.
Prozialeck et al.
(1) evaluated anti-CaM potency in about 50 phenothiazine derivatives, including CPZ, PMZ, and TFPZ, and showed that anti-CaM potency was in the order of TFPZ > CPZ > PMZ. In the present study, to gain a better understanding of the mechanisms underlying the effects of phenothiazine derivatives on bone resorption, we examined the effects of CPZ, TFPZ, and PMZ on osteoclast-like cell formation in cultures of mouse bone marrow cells (BMCs) treated with 1α,25(OH) 2 D 3 or soluble (s)-RANKL. We also examined the effects of CPZ, the selective CaM antagonist W7, or W5, the inactive analog of W7, on the formation of multinucleate osteoclast-like cells and the expression of mRNA for NFATc1, DC-STAMP, and general osteoclast markers in mouse BMCs treated with s-RANKL. Here, we demonstrated that CPZ inhibited RANKL-induced osteoclastogenesis, probably by its anti-CaM action.
Materials and Methods

Materials
Six-week-old ddY male mice were purchased from Japan SLC, Inc. (Hamamatsu) and treated in accordance with the Guidelines for Animal Experiments at the School of Dentistry, Aichi-Gakuin University. Chlorpromazine hydrochloride (CPZ), trifluoperazine hydrochloride (TFPZ), promethazine hydrochloride (PMZ), FK-506 monohydrate (calcineurin inhibitor), and fetal calf serum (FCS) were purchased from Sigma Co. (St. Louis, MO, USA). W7, a selective CaM antagonist; W5, an inactive analog of W7; KN-93, a general CaMK inhibitor; and KN-92, an inactive analog of KN-93, were purchased from MERCK KGaA (Darmstadt, Germany). Recombinant mouse s-RANKL was purchased from R&D (London, UK); 1α,25(OH) 2 D 3 , from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA, USA); and alpha-modified minimum essential medium (α-MEM), from Invitrogen Co. (Carlsbad, CA, USA). All other chemicals used were of reagent grade.
Cell culture and formation of TRAP-positive osteoclastlike cells
Mouse BMCs were obtained from tibiae as previously described (25) and cultured in plastic dishes in α-MEM containing FCS (10%), penicillin (100 IU/ml), and streptomycin (100 μg/ml) in humidified air with CO 2 (5%) at 37°C. To examine osteoclast formation, BMCs (10 6 cells) were cultured in 24-well plates for 7 days in α-MEM (1 ml) containing CPZ, PMZ, TFPZ (0.31 -10 μM), W7 (10 μM), W5 (10 μM), KN-93 (50 -1000 nM), KN-92 (50 -1000 nM), or FK506 (1 -1000 nM) in the presence of osteoclastogenesis-inducing drugs such as 1α,25(OH) 2 D 3 (10 nM) and s-RANKL (20 ng/ml). To avoid aspirating all of the non-adherent BMCs, including osteoclast precursors, we exchanged one-half (0.5 ml) of the supernatant of the culture medium for fresh medium every 2 days, and added drugs at the beginning of culture and at each change of the medium. After 7 days in culture, the adherent cells were fixed with a mixture of 10% formalin in phosphate-buffered saline and ethanol-acetone (50:50, v/v) and stained for TRAP by incubating the cells in sodium acetate buffer (0.1 M, pH 5) containing naphthol AS-MX phosphate and red-violet LB salt in the presence of sodium tartrate (10 μM), as described previously (26) . Cells containing 3 or more nuclei were designated as osteoclast-like cells. BMCs were also treated with CPZ (5 μM) for the first 3 days or the last 3 days during the culture period for 7 days in the presence of 1α,25(OH) 2 D 3 (10 nM). Cells treated with CPZ for 3 days were cultured for another 4 days in the presence of 1α,25(OH) 2 D 3 alone. Moreover, to examine the boneresorbing capability of osteoclast-like cells, we cultured BMCs in 24-well plates in which a dentin slice had been placed on the bottom of each well. After 7 days in culture, the cells were removed from the dentin slices, and resorption pits on the slices were stained with hematoxylin.
Analysis of mRNA levels by RT-PCR
For the experiment conducted to examine mRNA expression, BMCs were cultured for 5 days in 6-cmdiameter plastic dishes in α-MEM (5 ml) containing CPZ (5 μM), W7 (10 μM), or W5 (10 μM) in the presence of s-RANKL (20 ng/ml). One half of the culture medium was replaced every 2 days.
RNA was extracted from the cells by the guanidiumthiocyanate method (27) . The reverse transcriptionpolymerase chain reaction (RT-PCR) was performed by standard methods. Briefly, cDNA was first synthesized using random primers and Moloney murine leukemia virus reverse transcriptase (Gibco-BRL; Life Technologies, Grand Island, NY, USA), followed by PCR amplification using synthetic gene primers specific for mouse genes. The following forward and reverse primer sets (accession number of GenBank database) were used: 5′-CAACGCCCTGACCACCGATAG-3′ and 5′-GGCTG CCTTCCGTCTCATAGT-3′ for NFATc1 (NM_198429), 5′-CTAAGGAGAAGAAAACCCTTG-3′ and 5′-CA GCATAGAAGACAACAATCC-3′ for DC-STAMP (AY517483), 5′-TTGAGGACGTGTTCTCTGACC-3′ and 5′-TGGGCTGCTGACTGGCAAAGT-3′ for TRAP (S70805), 5′-GGCCAACTCAAGAAGAAAACT-3′ and 5′-ATAGCCCACCACCAACACTGC-3′ for cathepsin K (NM_007802), 5′-TTGGCTGTTTTGGGCTATTTT-3′ and 5′-CGCTTTGATCTTTCTATTCTT-3′ for CAII (K00811), 5′-AAGATGAGGCAAACCCACGAG-3′ and 5′-CCCGAGGAGCACTAACTACGC-3′ for CTR (U18542), and 5′-ACCACAGTCCATGCCATCAC-3′ and 5′-TCCACCACCCTGTTGCTGTA-3′ for GAPDH (NM_002046). Each PCR amplification mixture (25 μl) contained 2.5 μg cDNA. PCR amplification was performed using the GeneAmp PCR System (Perkin Elmer/ Cetus, Norwalk, CT, USA) under the following conditions: denaturation at 95°C for 15 s, annealing at 55°C for 30 s, and elongation at 72°C for 30 s. PCR products were electrophoresed on a 2% Nusive GTG agarose gel (FMC Bioproducts, Rockland, ME, USA), stained with ethidium bromide, and detected with a fluorescence imager analyzer (FluorImager 575; Amersham Pharmacia Biotech, Sunnyvale, CA, USA).
Statistical analysis
Data are presented as the mean ± S.E.M. The statistical significance of differences between groups was determined according to Tukey's multiple comparison tests. P < 0.05 was considered significant.
Results
Effect of CPZ on the formation of TRAP-positive osteoclast-like cells in mouse BMCs treated with 1α,25(OH) 2 D 3 or s-RANKL
The dose-relative effect of CPZ (0.31 -10 μM) on the formation of osteoclast-like cells generated by the treatment of BMCs with 1α,25(OH) 2 D 3 was examined ( Fig.  1: A and B ). TRAP-positive multinuclear large cells designated as osteoclast-like cells were clearly observed in cultures treated with 1α,25(OH) 2 D 3 (10 nM), which were significantly decreased by the addition of CPZ (0.63 -10 μM) dose-dependently. CPZ (5 μM) almost completely inhibited bone-resorbing activity in 1α,25(OH) 2 D 3 -induced osteoclast-like cells. Resorbing pits were clearly observed on the dentin slice in the BMCs treated with 1α,25(OH) 2 D 3 alone but not 1α,25(OH) 2 D 3 + CPZ (5 μM). Next, the effect of addition of CPZ (5 μM) in the first 3 days (1 -3 day), last 3 days (5 -7 day), or all 7 days (1 -7 day) on the formation of osteoclast-like cells was examined in the BMCs treated with 1α,25(OH) 2 D 3 (Fig. 1: C and D) . The formation of TRAP-positive cells was significantly inhibited by the treatment with CPZ for the last 3 days during osteoclastogenesis but not for the first 3 days. As shown in Fig. 2 , CPZ also decreased the number of TRAP-positive osteoclast-like cells generated by s-RANKL (20 ng/ml), dosedependently. Similar inhibition by CPZ in osteoclast-like cell formation was observed in BMCs treated with PGE 2 (data not shown).
Effects of CPZ, W7, and W5 on the formation of TRAPpositive osteoclast-like cells and the expression of mRNA for NFATc1, DC-STAMP, and general osteoclast markers in mouse BMCs treated with s-RANKL
Effects of CPZ (5 μM), W7 (10 μM), or W5 (10 μM) on the formation of TRAP-positive osteoclast-like cells were examined in BMCs treated with s-RANKL. As shown in Fig. 3 , the formation of TRAP-positive osteoclast-like cells was inhibited by W7 as well as CPZ. On the other hand, W5 had no effects on s-RANKL-induced osteoclast-like cell formation in their shape and number. Next, the effects on the expression of mRNA for NFATc1, DC-STAMP, and characteristic markers of osteoclasts, such as TRAP, cathepsin K, CAII, and CTR, were analyzed. As shown in Fig. 4 , expressions of mRNA for NFATc1, DC-STAMP, and osteoclast markers were all increased by s-RANKL alone, but were decreased by the addition of CPZ or W7, but not W5.
Effects of KN-93, KN-92, and FK506 on the formation of TRAP-positive osteoclast-like cells in mouse BMCs treated with s-RANKL
Effects of the CAMK inhibitor KN-93, KN-92 (inactive analogue of KN-93), and calcineurin inhibitor FK506 on the formation of TRAP-positive osteoclast-like cells was examined in mouse BMCs treated with s-RANKL. As shown in Fig. 5, A 
Effects of CPZ, TFPZ, and PMZ on the formation of TRAP-positive osteoclast-like cells in mouse BMCs treated with s-RANKL
We further examined effects of other phenothiazine derivatives on the formation of TRAP-positive osteoclast-like cells in mouse BMCs. As shown in Fig. 7 , CPZ, TFPZ, and PMZ dose-dependently inhibited the formation of osteoclast-like cells induced by s-RANKL. Osteoclast-like cell formation was inhibited by TFPZ, CPZ, and PMZ at lower concentrations (0.63 -2.5 μM) in the order of the potency of their CaM antagonistic action; however, osteoclastogenesis was almost completely inhibited by 3 phenothiazine derivatives at a concentration of 5 μM.
Discussion
In the present study, we demonstrated that the phenothiazine derivative CPZ inhibited osteoclast-like cell formation by its anti-CaM action in mouse BMCs treated (Fig. 1: A and B) . CPZ (5 μM) almost completely inhibited not only TRAP-positive osteoclastlike cell formation but also resorption pit formation on dentin slice suggesting that 5 μM was a sufficient concentration of CPZ to inhibit the 1α,25(OH) 2 D 3 -induced formation of osteoclast-like cells with resorption activity. To clarify which stage of 1α,25(OH) 2 D 3 -induced osteoclastic differentiation was inhibited by CPZ, effects of addition of CPZ (5 μM) in the first 3 days, last 3 days, or total 7 days on the formation of osteoclast-like cells were examined (Fig. 1: C and D) . The formation of TRAPpositive cells was significantly inhibited by the treatment with CPZ for the last 3 days during osteoclastogenesis but not for the first 3 days, suggesting that CPZ might inhibit the late stage of differentiation from bone marrow macrophages to osteoclasts. As shown in Fig. 2 , CPZ also inhibited the formation of TRAP-positive osteoclastlike cells generated by s-RANKL given exogenously, suggesting that CPZ directly inhibited osteoclast differentiation triggered by RANKL-RANK interaction.
Recently, the precise molecular mechanisms underlying osteoclast differentiation via RANKL-RANK signaling have been clarified (18 -23) . In osteoclast precursor cells, the binding of RANKL to RANK specifically induced intracellular Ca 2+ oscillations, which would contribute to the sustained activation of NFATc1 via a CaM-calcineurin-dependent mechanism (19, 24, 28) and CaM-CaMKIV-CREB pathway (23) . Judging from these literature, it seems possible that anti-CaM drugs modulate the critical intracellular signaling pathway involved in osteoclastogenesis.
In the present study, we showed that CPZ and W7 inhibited the formation of osteoclast-like cells (Fig. 3 ) and the expression of mRNA for NFATc1, DC-STAMP, and characteristic markers of osteoclasts in mouse BMCs treated with s-RANKL (Fig. 4) . In contrast, W5 without anti-CaM action did not affect osteoclastogenesis or the mRNA expressions described above. These results were well consistent with the study of Zhang et al. (8) who demonstrated that CaM antagonists, TFPZ, W7, and tamoxifen, dose-dependently inhibited osteoclast formation using mouse bone marrow macrophages. Furthermore, treatment of mouse BMCs with the general CaMK inhibitor KN-93 but not its inactive control KN-92 inhibited osteoclast-like cell formation by s-RANKL (Fig. 5:  A and B) , which is consistent with Sato's study (23) previously demonstrating that KN-93 but KN-92 specifically and powerfully suppressed the osteoclastogenesis. The calcineurin inhibitor FK506 decreased osteoclastlike cell formation by s-RANKL ( Fig. 5: C and D) . To clarify an involvement of CPZ in CaMK or the calcineurin pathway, we examined the effect of CPZ (1.25 μM) on osteoclastogenesis in the presence of KN-93 (50 nM) or FK506 (1 nM). Concentrations of CPZ, KN-93, and FK506 showing partial inhibition in osteoclastogenesis were used. As shown in Fig. 6 , the inhibitory effect of CPZ on osteoclast-like cell formation was increased in the presence of FK506 but not KN-93, suggesting that CPZ might be involved in the calcineurin pathway. However, further questions remain about why CPZ might be involved in osteoclastogenesis via the calcineurin pathway. More studies are needed to elucidate the mechanism underlying CPZ action on the downstream pathways of Ca 2+ -CaM. In any case, the present results suggested that CPZ inhibited osteoclastogenesis, possibly via modulating RANKL-RANK signals, leading to the activation of NFATc1 by its anti-CaM action. To clarify this notion, we examined the effects of phenothiazine derivatives with different anti-CaM potency on the osteoclastlike cell formation induced by s-RANKL. Prozialeck et al. (1) determined the IC 50 concentration of drug needed to inhibit the CaM-induced activation of phosphodiesterase by 50%, for about 50 phenothiazine derivatives, and estimated their anti-CaM potency. Referring to their study, we selected TFPZ, CPZ, and PMZ because the IC 50 was 17 μM for TFPZ, 40 μM for CPZ and 340 μM for PMZ, suggesting that TFPZ, CPZ, and PMZ are strong, medium, and weak drugs with regards to anti-CaM potency, respectively. As shown in Fig. 7 , all three phenothiazine derivatives inhibited osteoclast-like cell formation. Osteoclastogenesis inhibitory effects decreased in the order of TFPZ, CPZ, PMZ, depending on their anti-CaM potency. This evidence suggested that CPZ probably inhibited the Ca 2+ -CaM signaling pathway by anti-CaM action, resulting in the inhibition of NFATc1 expression and osteoclastogenesis.
CPZ is known to cause occasional toxic reactions such as hepatitis with jaundice, hypoplastic anemia, and der- matitis. Moreover, growth retardation and malformation by the slow progress of ossification in the offspring of CPZ-treated pregnant animals has been demonstrated (29 -31) . In addition, we also demonstrated that CPZ inhibited alkaline phosphatase activity and mineralization in tooth germ culture (32) . However, photographs of BMCs in the present study showed no inhibitory effect of CPZ on the survival of BMCs (Fig. 1 : Ac and Cd, Fig.  2 : Ad, Fig. 3: Ab) . From the evidence observed in this study, we concluded that the phenothiazine derivative CPZ inhibited osteoclastogenesis in mouse BMCs treated with s-RANKL by anti-CaM action but not toxic action.
In previous studies, the anti-bone resorbing effects of phenothiazines were observed in experimental periodontal disease in rats with a nylon thread ligature around the cervix of the second left upper molars in vivo (9) and in calvaria and isolated osteoclast cultures in vitro (5 -7). The bulk of these studies suggesting that the phenothiazine derivatives inhibited bone resorption by inhibiting osteoclast differentiation and the activity were not inconsistent with the present results. Although further studies are needed to elucidate the full mechanism of the inhibitory effects of CPZ on bone resorption, the present study clearly shows that CPZ inhibits osteoclastogenesis through its anti-CaM action.
In conclusion, phenothiazine derivatives such as CPZ inhibit RANKL-induced osteoclastogenesis through anti-CaM actions. 
